KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2017 - 2025)

Alnylam Pharmaceuticals' Net Cash Flow history spans 17 years, with the latest figure at $171.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 247.29% year-over-year to $171.7 million; the TTM value through Dec 2025 reached $655.2 million, up 287.69%, while the annual FY2025 figure was $655.2 million, 287.69% up from the prior year.
  • Net Cash Flow reached $171.7 million in Q4 2025 per ALNY's latest filing, down from $377.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $495.6 million in Q3 2022 to a low of -$283.7 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $57.5 million, with a median of $44.9 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 8701.27% in 2021, then soared 2124.43% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$271.3 million in 2021, then increased by 23.15% to -$208.5 million in 2022, then dropped by 10.92% to -$231.2 million in 2023, then surged by 49.58% to -$116.6 million in 2024, then skyrocketed by 247.29% to $171.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Net Cash Flow are $171.7 million (Q4 2025), $377.9 million (Q3 2025), and $66.1 million (Q2 2025).